EMEmily Miyoshi

Emily Miyoshi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emily Miyoshi has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-nucleus multi-omics identifies shared and distinct pathways in Pick’s and Alzheimer’s disease

    by Zechuan Shi, Sudeshna Das, Samuel Morabito, Jennifer Stocksdale, Emily Miyoshi, Shushrruth Sai Srinivasan, Nora Emerson, Arshi Shahin, Negin Rahimzadeh, Zhenkun Cao, et al.

    The study of transcriptomic and epigenomic variations in neurodegenerative diseases, particularly tauopathies like Pick’s disease (PiD) and Alzheimer’s disease (AD), offers insights into their underlying regulatory mechanisms. Here, we identified critical regulatory changes driving disease progression, revealing potential therapeutic targets. Our comparative analyses uncovered disease-enriched noncoding regions and genome-wide transcription factor (TF) binding differences, linking them to target genes. Notably, we identified a distal human-gained enhancer (HGE) associated with E3 ubiquitin ligase (UBE3A), highlighting disease-specific regulatory alterations. Additionally, fine mapping of AD risk genes uncovered loci enriched in microglial enhancers and accessible in other cell types. Shared and distinct TF binding patterns were observed in neurons and glial cells across PiD and AD. We validated our findings using CRISPR to excise a predicted enhancer region in UBE3A and developed an interactive database, scROAD, to visualize predicted single-cell TF occupancy and regulatory networks.


  • Open Access

    Splice-modulating antisense oligonucleotides targeting a pathogenic intronic variant in adult polyglucosan body disease correct mis-splicing and restore enzyme activity in patient cells

    by Ria Thomas, Emily Miyoshi, Hasan O Akman, Sophie H R Storz, Joy Goffena, Julia Pytte, Danny E Miller, Konstantina Skourti-Stathaki, Stanley T Crooke

    Adult polyglucosan body disease (APBD) is a rare, adult-onset neurodegenerative disorder caused by loss-of-function variants in the glycogen branching enzyme (GBE1) gene, essential for glycogen biosynthesis. The second most common pathogenic mutation in APBD (c.2053-3358_2053-3350delinsTGTTTTTTACATGACAGGT) is a deep intronic deletion insertion (indel) variant creating an ectopic splice acceptor site, resulting in a mutant transcript with a pseudoexon encoding an unstable truncated protein. Such mutations can be effectively targeted with splice-modulating antisense oligonucleotides (ASOs) to restore normal splicing. Here, we characterized the indel in-depth using long-read sequencing techniques and discovered several new features of the mutant transcript. The indel sequence varies from the previously identified sequence by a nucleotide, and the usage of the ectopic splice site results in two mutant isoforms, both of which are targets of cellular nonsense-mediated decay. High-throughput screening in patient-derived fibroblasts identified multiple lead candidates that effectively blocked the ectopic splice site and increased the canonical GBE1 transcript and protein. Functional analysis confirmed that treatment with the lead ASOs significantly improved GBE1 enzyme activity in patient cells, validating their therapeutic potential. Taken together, our data demonstrate the successful discovery of ASOs that correct mis-splicing, thus offering a promising treatment for a subset of APBD patients.


  • Top Cited Papers
    Open Access

    Spatial and single-nucleus transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease

    by Emily Miyoshi, Samuel Morabito, Caden M. Henningfield, Sudeshna Das, Negin Rahimzadeh, Sepideh Kiani Shabestari, Neethu Michael, Nora Emerson, Fairlie Reese, Zechuan Shi, et al.

    The pathogenesis of Alzheimer’s disease (AD) depends on environmental and heritable factors, with its molecular etiology still unclear. Here we present a spatial transcriptomic (ST) and single-nucleus transcriptomic survey of late-onset sporadic AD and AD in Down syndrome (DSAD). Studying DSAD provides an opportunity to enhance our understanding of the AD transcriptome, potentially bridging the gap between genetic mouse models and sporadic AD. We identified transcriptomic changes that may underlie cortical layer-preferential pathology accumulation. Spatial co-expression network analyses revealed transient and regionally restricted disease processes, including a glial inflammatory program dysregulated in upper cortical layers and implicated in AD genetic risk and amyloid-associated processes. Cell–cell communication analysis further contextualized this gene program in dysregulated signaling networks. Finally, we generated ST data from an amyloid AD mouse model to identify cross-species amyloid-proximal transcriptomic changes with conformational context.


  • Open Access

    Integrated spatial and single‐cell transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease

    by Samuel Morabito, Emily Miyoshi, Caden M Henningfield, Zechuan Shi, Neethu Michael, Sepideh Kiani Shabestari, Sudeshna Das, Saba Shahin, Elizabeth Head, Kim N Green, et al.

    Background: The pathogenesis of Alzheimer’s disease (AD) varies greatly depending on environmental and heritable factors. Neuropathological scores aid in the understanding of disease severity in postmortem tissue, but fail to provide insights into disease onset and progression. Conversely, mouse models of AD like 5XFAD offer predictable timelines of amyloid accumulation due to specific human AD risk signals, but have limitations due to species differences. Studying AD in Down Syndrome (AD in DS) patients provides an opportunity to study the transcriptomics of AD progression due to overexpression of APP, which results in a more predictable disease time course compared to the more stochastic disease progression in the general population.Method: We present a rigorous transcriptomic analysis of AD using single‐nucleus RNA‐seq (snRNA‐seq) and spatial transcriptomics (ST) in cortical samples from donors with early‐stage AD, late‐stage AD, AD in DS, and cognitively normal controls. We performed ST (10X Genomics Visium) in these groups, and additionally performed snRNA‐seq (Parse Biosciences) in tissue from AD in DS donors and controls. Finally, we profiled 5XFAD and wild type mice at four time points (4, 6, 8, and 12 months) using ST to facilitate cross‐species comparisons. We applied state‐of‐the‐art bioinformatic and statistical approaches to integrate these datasets with published AD snRNA‐seq data and to perform systematic analyses of gene expression and gene networks in these groups.Result: We found shared and distinct differentially expressed genes (DEGs) between AD and AD in DS in the ST and snRNA‐seq datasets, with greater concordance in neuronal cell types compared to glia. Cell‐cell communication network analysis of integrated snRNA‐seq and ST data revealed vast network remodeling in disease, highlighting an increase in WNT and ANGPTL signaling and a decrease in CD99 signaling among other disrupted pathways. Using geospatial statistical analysis, we identified amyloid plaque proximal DEGs in human and mouse ST data, which were largely species‐specific with little overlap.Conclusion: The primary data generated here will be a valuable resource for the AD community, and our study provides new insights into the transcriptomics of AD and amyloid pathology by performing a holistic analysis considering sporadic and genetic forms of AD.


  • Open Access

    EXPLORING PLAQUE-ASSOCIATED GENE EXPRESSION IN ALZHEIMER'S DISEASE THROUGH SPATIAL TRANSCRIPTOMICS IN HUMAN AND MOUSE MODELS

    by Emily Miyoshi, Samuel Morabito, Sudeshna Das, Kim Green, Elizabeth Head, Vivek Swarup

  • Open Access

    Huntington disease oligodendrocyte maturation deficits revealed by single-nucleus RNAseq are rescued by thiamine-biotin supplementation

    by Ryan G. Lim, Osama Al-Dalahmah, Jie Wu, Maxwell P. Gold, Jack C. Reidling, Guomei Tang, Miriam Adam, David K. Dansu, Hye-Jin Park, Patrizia Casaccia, et al.

    The complexity of affected brain regions and cell types is a challenge for Huntington’s disease (HD) treatment. Here we use single nucleus RNA sequencing to investigate molecular pathology in the cortex and striatum from R6/2 mice and human HD post-mortem tissue. We identify cell type-specific and -agnostic signatures suggesting oligodendrocytes (OLs) and oligodendrocyte precursors (OPCs) are arrested in intermediate maturation states. OL-lineage regulatorsOLIG1andOLIG2are negatively correlated with CAG length in human OPCs, and ATACseq analysis of HD mouse NeuN-negative cells shows decreased accessibility regulated by OL maturation genes. The data implicates glucose and lipid metabolism in abnormal cell maturation and identifyPRKCEand Thiamine Pyrophosphokinase 1 (TPK1) as central genes. Thiamine/biotin treatment of R6/1 HD mice to compensate forTPK1dysregulation restores OL maturation and rescues neuronal pathology. Our insights into HD OL pathology spans multiple brain regions and link OL maturation deficits to abnormal thiamine metabolism.


  • Open Access

    Absence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice

    by Sepideh Kiani Shabestari, Samuel Morabito, Emma Pascal Danhash, Amanda McQuade, Jessica Ramirez Sanchez, Emily Miyoshi, Jean Paul Chadarevian, Christel Claes, Morgan Alexandra Coburn, Jonathan Hasselmann, et al.


  • Open Access

    Exosomal tau with seeding activity is released from Alzheimer's disease synapses, and seeding potential is associated with amyloid beta

    by Emily Miyoshi, Tina Bilousova, Mikhail Melnik, Danyl Fakhrutdinov, Wayne W. Poon, Harry V. Vinters, Carol A. Miller, Maria Corrada, Claudia Kawas, Ryan Bohannan, et al.


  • Top Cited Papers

    Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease

    by Samuel Morabito, Emily Miyoshi, Neethu Michael, Saba Shahin, Alessandra Cadete Martini, Elizabeth Head, Justine Silva, Kelsey Leavy, Mari Perez-Rosendahl, Vivek Swarup

    The gene-regulatory landscape of the brain is highly dynamic in health and disease, coordinating a menagerie of biological processes across distinct cell types. Here, we present a multi-omic single-nucleus study of 191,890 nuclei in late-stage Alzheimer’s disease (AD), accessible through our web portal, profiling chromatin accessibility and gene expression in the same biological samples and uncovering vast cellular heterogeneity. We identified cell-type-specific, disease-associated candidate cis-regulatory elements and their candidate target genes, including an oligodendrocyte-associated regulatory module containing links to APOE and CLU. We describe cis-regulatory relationships in specific cell types at a subset of AD risk loci defined by genome-wide association studies, demonstrating the utility of this multi-omic single-nucleus approach. Trajectory analysis of glial populations identified disease-relevant transcription factors, such as SREBF1, and their regulatory targets. Finally, we introduce single-nucleus consensus weighted gene coexpression analysis, a coexpression network analysis strategy robust to sparse single-cell data, and perform a systems-level analysis of the AD transcriptome.


  • Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4

    by Tina Bilousova, Mikhail Melnik, Emily Miyoshi, Bianca L. Gonzalez, Wayne W. Poon, Harry V. Vinters, Carol A. Miller, Maria M. Corrada, Claudia Kawas, Asa Hatami, et al.